Andere Sprachen Lantern Pharma Inc.

Aktien

A2P5NM

US51654W1018

LTRN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
4.67 ^USD	+2.86%		+12.53%	+9.11%

12.06.	Lantern Pharma sichert sich ein Patent auf die Zusammensetzung des Wirkstoffs LP-284 in Japan	MT
12.06.	Lantern Pharma Inc. erhält Patentzertifikat vom japanischen Patentamt für die Zusammensetzung des Wirkstoffs LP-284	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284	13.06.
Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan	12.06.
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284	12.06.
Lantern Pharma Inc. Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284	12.06.
Lantern Pharma : Corporate Overview	03.06.
Lantern Pharma Files $150 Million Mixed Shelf	24.05.
Lantern Pharma : Corporate Overview	13.05.
Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...	13.05.
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights	09.05.
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration	06.05.
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism	06.05.
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications	06.05.
Lantern Pharma to Report First Quarter 2024 Operating and Financial Results on May 9th, 2024 at 4:30 p.m. ET	03.05.
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET	02.05.
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	25.04.
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	24.04.
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	23.04.
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion	22.04.
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	22.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lantern Pharma Inc.

Aktien

A2P5NM

US51654W1018

LTRN

Andere Sprachen

Filter